the PERSEPHONE trial in early HER2+ breast cancer

Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting Author: obr Added: 07/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts